ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

ClinicalTrials.gov ID: NCT07402876

Public ClinicalTrials.gov record NCT07402876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Double-masked, Dosing-frequency-controlled, Multicenter Clinical Trial Evaluating the Safety and Activity of Intravitreally Injected ADX-2191 (Methotrexate Injection USP) in Patients With Primary Vitreoretinal Lymphoma

Study identification

NCT ID
NCT07402876
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

  • ICM ADX-2191 injection Drug
  • Monthly ADX-2191 injection Drug

Drug

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026
Last update posted
Feb 10, 2026

2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Bascom Palmer Eye Institute Miami Florida 33101 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07402876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07402876 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →